|
Coverage for individual vaccine doses |
|||||
| Age group (months) |
I (0 – 8) |
II (9 – 11) |
III (12 – 23) |
IV (24 – 35) |
Total |
| Number (%) |
Number (%) |
Number (%) |
Number (%) |
||
|
|
|||||
| Total in group |
46 (100) |
58 (100) |
83 (100) |
99 (100) |
286 (100) |
| BCG |
39 (85) |
48 (83) |
73 (88) |
91 (92) |
251 (88) |
| OPV-1 |
38 (83) |
49 (85) |
71 (86) |
85 (86) |
243 (85) |
| OPV-2 |
34 (74) |
45 (78) |
64 (77) |
77 (78) |
220 (77) |
| OPV-3 |
25 (54) |
37 (64) |
57 (69) |
71 (72) |
190 (66) |
| DTP-1 |
38 (83) |
49 (84) |
70 (84) |
84 (85) |
241 (84) |
| DTP-2 |
34 (74) |
45 (78) |
63 (76) |
76 (77) |
218 (76) |
| DTP-3 |
25 (54) |
37 (64) |
58 (70) |
70 (71) |
190 (66) |
| Measles |
- |
16 (28) |
55 (66) |
68 (69) |
139 (58)* |
| DTP Booster |
- |
- |
10 (12) |
8 (8) |
18 (10)** |
| Measles Booster |
- |
- |
14 (17) |
11 (11) |
25 (14)** |
|
* Proportion based on 240 children eligible for vaccination. ** Proportion based on 182 children eligible for vaccination. | |||||
Senessie et al. Conflict and Health 2007 1:14 doi:10.1186/1752-1505-1-14 |
|||||